Asset Details
Do you wish to reserve the book?
Should breast surgery be considered for patients with de novo metastatic inflammatory breast cancer?
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Should breast surgery be considered for patients with de novo metastatic inflammatory breast cancer?
Do you wish to request the book?
Should breast surgery be considered for patients with de novo metastatic inflammatory breast cancer?
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Should breast surgery be considered for patients with de novo metastatic inflammatory breast cancer?
2024
Overview
We aimed to identify factors predicting surgery for de novo stage IV inflammatory breast cancer (IBC) and determine the association of surgery with overall survival (OS).
Female patients with unilateral AJCC clinical stage IV IBC treated 2010–2018 in the NCDB were identified. Logistic regression and multivariable proportional Cox hazards regressions determined factors associated with treatment and OS.
Of 1049 patients, 29.1% underwent breast surgery (BS) and 70.9% had no surgery (NS). Increasing age and more recent treatment year were significantly associated with NS. 2-Year OS was superior in BS patients (71% vs 38% NS). Single-site and bone-only metastasis had no association with treatment type or OS.
Contrary to guidelines, 1/3 of de novo stage IV IBC patients underwent BS, and had an independent OS benefit irrespective of extent or site of metastasis. Further research is needed to determine which patients with stage IV IBC should undergo BS.
•Breast surgery for de novo stage IV breast cancer is contraindicated by guidelines.•Up to one-third of patients with de novo stage IV inflammatory breast cancer in a national cohort undergo this intervention.•Breast surgery was associated with an independent overall survival benefit irrespective of extent or site of metastasis.
Publisher
Elsevier Inc,Elsevier Limited
